

LaBelforte rooting for nasal sprays and pocket inhalers to tackle COVID-19

19 January 2022 | News

Sets up special purpose entities to take forward the idea of developing new products



LaBelforte, a startup promoted by a Pune-based doctor, has announced the launch of its special purpose business entities – Covidrops and Covinhaler to facilitate the development of immune optimising nasal and inhaled drug products.

"Company's target is to primarily facilitate co-development of Nasal sprays and Pocket Inhaler that are safe and effective ancillaries for both COVID-19 prophylaxis and therapy," Dr Gaurav Raj Chhabra, Founder, LaBelforte, India.

"Our immediate attention is on host-directed therapeutic options, that safely and efficiently optimize mucosal and barrier immunity by potentiating body's own immune system through Immunogenic gene expression," says, Chhabra, who has been scrutinizing the international developments in the category for over 18 months now.

As a first-line barrier to viral entry and viral shedding, intranasal/ inhalation drug products bolstering mucosal immunity may offer a remarkable advantage in the prevention and control of COVID-19.

Once it goes through all the requisite regulatory approvals, and with competent Industry alliances in place, it plans to clear grounds for facilitating the launch of its flagship products through its special purpose entities- COVIDROPS™ and COVINHALER® in India by the second quarter of 2022 and parallelly explore the International markets as well.